Title: Immunity to *Streptococcus pyogenes* and Common Respiratory Viruses at Age 0-4 Years after COVID-19 restrictions

Subtitle: A Cross-Sectional Study

Kitt Dokal MBBS[1]*

Samuel Channon-Wells MMath[1,2,3]*

Catherine Davis BSc[4]

Diego Estrada-Rivadeneyra PhD[1,2]

Kristin K Huse PhD[1,5]

Amelia Lias MRes[1,5]

Shea Hamilton PhD[1.2]

Rebecca L Guy MSc[6]

Theresa Lamagni PhD[6,7]

Sam Nichols PhD[1,2]

Andrew Taylor PhD[4]

Philipp KA Agyeman MD[8]

Amutha Anpananthar MSc[9]

Romain Basmaci PhD[10,11]

Enitan D Carrol MD[12,13]

Michael J Carter Dphil[14]

Tisham De PhD[1,2]

Marien I de Jonge PhD[15,16]

Marieke Emonts PhD[17,18,19]

Leire Estramiana Elorrieta MSc[1,2]

Katy Fidler PhD[20,21]

Mojca Kolnik MD[22]

Taco W Kuijpers PhD[23,24]

Federico Martinon-Torres PhD[25,26,27]

Henriette Moll PhD[28]

Marine Mommert-Tripon PhD[29,30,31]

Samira Neshat MD[9]

Maggie Nyirenda-Nyang'wa PhD[32]

Sean O'Riordan PhD[33]

Daniel R Owens MRCPCH[34]

Nazima Pathan FRCPCH[35]

Stephane Paulus MD[36,37]

Mark J Peters PhD[38]

Marko Pokorn PhD[22,39,40]

Andrew J Pollard FRS[36,37]

Irene Rivero Calle PhD[25,26]

Pablo Rojo PhD[41,42]

Lorenza Romani MD[43]

Prita Rughani MRCPCH[9]

Luregn J Schlapbach PhD[44,45]

Nina A Schweintzger PhD[46]

Ching-Fen Shen MD[47]

Artur Sulik PhD[48]

Maria Tsolia PhD[49]

Effua Usuf PhD[50]

Michiel van der Flier PhD[51]

Clementien Vermont PhD[52]

Ulrich von Both FRCPCH[53,54]

Paul Wellman MRes[14]

Victoria J Wright PhD[1,2]

Shunmay Yeung PhD[55,56,57]

Dace Zavadska PhD[58]

Aubrey J Cunnington FRCPCH[1,2]

Colin Fink PhD[4]

Jethro Herberg PhD[1,2]

Myrsini Kaforou PhD[1,2]

PERFORM Consortium

DIAMONDS Consortium

Shiranee Sriskandan FRCP[1,5,7]

Michael Levin FMedSci[1,2]

Tom Parks MD[1]

*Equal contribution

1. Department of Infectious Disease, Imperial College London, London, United Kingdom

2. Centre for Paediatrics and Child Health, Imperial College London, London, United Kingdom

3. UKRI Centre for Doctoral Training in AI for Healthcare, Imperial College London, London, United Kingdom

4. Micropathology Ltd, Coventry, United Kingdom

5. Centre for Bacterial Resistance Biology, Imperial College London, London, United Kingdom

6. Antimicrobial Resistance & Healthcare-Associated Infection Division, UK Health Security Agency, London, United Kingdom

7. NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London and UK Health Security Agency, London, United Kingdom

8. Department of Pediatrics, Inselspital, Bern University Hospital, University of Bern, Switzerland

9. Barts Health NHS Trust, Whitechapel Road, London, E1 1FR, United Kingdom

10. Service de Pédiatrie-Urgences, AP-HP, Hôpital Louis-Mourier, F-92700 Colombes, France

11. Université Paris Cité, Inserm, IAME, F-75018 Paris, France

12. Department of Clinical Infection, Microbiology and Immunology, University of Liverpool Institute of Infection, Veterinary and Ecological Sciences, Liverpool, United Kingdom

13. Alder Hey Children's Hospital, Department of Infectious Diseases, Eaton Road, Liverpool, L12 2AP, United Kingdom

14. Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

15. Laboratory of Medical Immunology, Radboud Institute for Medical Innovation, Radboud UMC, Nijmegen, Netherlands

16. Radboud Community for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands

17. Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom

18. Great North Children's Hospital, Paediatric Immunology, Infectious Diseases & Allergy, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

19. NIHR Newcastle Biomedical Research Centre based at Newcastle upon Tyne Hospitals NHS Trust and Newcastle University, Westgate Rd, Newcastle upon Tyne, NE4 5PL, United Kingdom

20. Brighton and Sussex Medical School, University of Sussex, East Sussex, BN1 9PX, United Kingdom

21. Royal Alexandra Children's Hospital, Brighton, BN2 5BE, United Kingdom

22. University Childrens' Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia

23. Amsterdam University Medical Center (Amsterdam UMC), location Academic Medical Center (AMC), Dept of Pediatric Immunology, Rheumatology and Infectious Diseases, University of Amsterdam, Amsterdam, the Netherlands

24. Sanquin Research Institute, & Landsteiner Laboratory at the AMC, University of Amsterdam, Amsterdam, the Netherlands.

25. Translational Pediatrics and Infectious Diseases, Pediatrics Department, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain

26. GENVIP Research Group (www.genvip.org), Instituto de Investigación Sanitaria de Santiago, Universidad de Santiago de Compostela, Galicia, Spain

27. CIBER of Respiratory Diseases (CIBERES), Instituto de Salud Carlos III, Madrid 28222, Spain

28. Department of General Paediatrics, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands

29. Innovation & Partnerships (I&P), bioMérieux S.A., Marcy l'Etoile, France

30. Joint research unit Hospice Civils de Lyon - bioMérieux, Centre Hospitalier Lyon Sud, 165 Chemin du Grand Revoyet, 69310 Pierre-Bénite, France

31. EA 7426 Pathophysiology of Injury-induced Immunosuppression, University of Lyon1-Hospices Civils de Lyon-bioMérieux, Hôpital Edouard Herriot, 5 Place d'Arsonval, 69437 Lyon Cedex 3, France

32. Lewisham and Greenwich NHS Trust, Lewisham High Street, London, SE13 6LH, United Kingdom

33. Leeds Children's Hospital, Great George Street, Leeds, LS1 3EX, United Kingdom

34. NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom

35. Department of Paediatrics, University of Cambridge, Addenbrookes Hospital, Hills Road, Cambridge CB2 0QQ, United Kingdom

36. Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom

37. NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom

38. Great Ormond Street Hospital for Children NHS Foundation Trust, Guilford St, London WC1N 3BH, United Kingdom

39. Department of Infectious Diseases, University Medical Centre Ljubljana, Japljeva 2, SI-1525 Ljubljana, Slovenia

40. Department of Infectious Diseases and Epidemiology, Faculty of Medicine, University of Ljubljana, Slovenia

41. Servicio Madrileño de Salud (SERMAS),Pediatric Infectious Diseases Unit, Department of Pediatrics, Hospital Universitario 12 de Octubre, Madrid, Spain

42. Universidad Complutense de Madrid, Faculty of Medicine, Department of Pediatrics, Madrid, Spain.

43. Infectious Disease Unit, Academic Department of Pediatrics, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

44. Department of Intensive Care and Neonatology, University Children`s Hospital Zurich, University of Zurich, Zurich, Switzerland

45. Child Health Research Centre, University of Queensland, Brisbane, Australia

46. Department of Pediatrics and Adolescent Medicine, Division of General Pediatrics, Medical University of Graz, Graz, Austria

47. Department of Pediatrics, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan City, Taiwan

48. Department of Pediatric Infectious Diseases, Medical University of Bialystok, Poland

49. National and Kapodistrian University of Athens, 2nd Department of Paediatrics, "P. and A. Kyriakou" Children's Hospital, Greece

50. Medical Research Council Unit The Gambia at LSHTM, PO Box 273, Fajara, The Gambia

51. Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, The Netherlands

52. Erasmus MC-Sophia Children's Hospital, Department of Paediatric Infectious Diseases & Immunology, Rotterdam, the Netherlands

53. Division of Paediatric Infectious Diseases, Hauner Children's Hospital, University Hospital, Ludwig Maximilians University (LMU), Munich, Germany

54. German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany

55. Faculty of Infectious and Tropical Disease, London School of Hygiene and Tropical Medicine, London, United Kingdom

56. Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom

57. Department of Paediatrics, St. Mary's Hospital Imperial College Hospital, London, United Kingdom

58. Riga Stradins university, Riga, Latvia; Children clinical university hospital, Riga, Latvia

Correspondence to: Professor Shiranee Sriskandan (s.sriskandan@imperial.ac.uk), Professor Michael Levin (m.levin@imperial.ac.uk) and Dr Tom Parks (t.parks@imperial.ac.uk)

ABSTRACT

Importance: The upsurge in invasive disease caused by *Streptococcus pyogenes* among children reported in several European countries during 2022-2023 has not been fully explained.

Objective: To test the hypothesis that changes in circulation of common respiratory pathogens associated with the introduction of non-pharmaceutical interventions (NPIs) during the COVID-19 pandemic altered acquisition of immunity to *S. pyogenes* and common respiratory viruses.

Design: Cross-sectional study recruiting before (September 2016 to March 2020) and after (April 2020 to July 2023) introduction of NPIs.

Setting: European hospitals in 10 countries.

Participants: Children with suspected infection and afebrile controls, aged 0-4 years.

Main Outcomes: Molecular detection of bacterial and viral pathogens on throat swabs and age-stratified total serum IgG reactivity to *S. pyogenes* cell wall extract from two strains (measured by ELISA), and respiratory syncytial virus (RSV), five influenza viruses and four common cold coronaviruses and SARS-CoV-2 measured by Mesoscale immunoassay.

Results: Throat swabs from 1942 children under 5-years of age were tested for respiratory pathogens (1449 recruited before introduction of NPIs; 493 recruited after). A decrease in detection of *S. pyogenes,* RSV, common cold coronaviruses, and influenza viruses was observed between March 2020 to July 2021, corresponding to the maximal period of NPIs. Antibodies to *S. pyogenes* were measured in 252 children recruited before NPIs and 200 thereafter. Antibodies to viral antigens were measured in 230 before NPIs and 92 thereafter. Total IgG to *S. pyogenes* and RSV was significantly lower in children aged 3-4 years recruited after NPI introduction compared with before (*S. pyogenes emm1*: after, n=67, median 0.13 vs before, n=87, 0.35 IVIG relative-units, p=0.007. RSV: after, n=30, median 49604 vs before, n=76, 141782 mesoscale-units p<0.001). No such differences were observed for children aged 0-2 years, or for individual influenza viruses, common cold coronaviruses or SARS-CoV-2.

Conclusions and Relevance: We found a significant reduction in serum antibodies to *S. pyogenes* and RSV in children aged 3-4 years after introduction of NPIs. Equivalent to approximately a year delay in acquisition of immunity, these data provide a biological basis for the 2022-2023 upsurge in severe *S. pyogenes* infections in this age group.

Background

A multi-country outbreak of severe invasive *Streptococcus pyogenes* (iGAS) infections was reported in the fourth quarter of 2022, with greatest impact on children under 10 years of age. This featured unusually severe presentations including rapidly progressive empyema, and septic shock.[1-3] In the United Kingdom (UK), where infections normally peak between the first and second quarter,[4] both iGAS disease and scarlet fever are notifiable. However, a sharp out-of-season increase in scarlet fever notifications in the fourth quarter was matched by a sharp increase in primary care consultations for streptococcal pharyngitis: both preceded a peak in iGAS notifications.[1] For example, in the UK, surveillance of *S. pyogenes* strains causing iGAS demonstrated an initial expansion of *emm12* strains in the second and third quarters of 2022, followed by a rapid increase in *emm1 S. pyogenes* strains – mirrored in several European countries – in the fourth quarter of 2022, such that *emm1* accounted for approximately 70% of severe paediatric infections.[4-7] Many of the children admitted to hospital with severe iGAS infection were reported to have coinfections with respiratory viruses, in particular RSV.[4,8] Moreover, coinfection with respiratory viruses was identified in more than half of the UK children who died in the community from iGAS infection during this period.[9]

Reduced exposure to common respiratory viruses and bacteria during the period of COVID-19-related restrictions has been postulated to result in loss of population immunity to common childhood pathogens.[10] Scarlet fever is a disease that most commonly affects children in their first year at school.[11] In the UK, and other European countries, school attendance was markedly reduced from March 2020 leading to reduced exposure to *S. pyogenes*, rates of which fell markedly during the period March 2020-March 2022.[2,12] The term “immunity debt” was proposed by Cohen *et al.,* who suggested that reduced circulation of common pathogens as a result of non-pharmaceutical interventions (NPIs) resulted in impaired community immunity to common infectious agents, and thus to an increase in severe childhood illness when normal social interaction returned.[13] The concept of immune

debt (also called “immunity gap”) has been widely debated in the scientific literature and popular press.[14,15] However, although it is a plausible explanation for the increase in childhood illness following relaxation of pandemic social distancing measures, there is so far little biological data to support this hypothesis.[16]

Accordingly, using serum samples from children presenting to hospital as an indicator of community-level immunity in children, we investigated whether a reduction in acquisition of antibody-mediated immunity to common respiratory pathogens could be detected when comparing samples collected before and after introduction of NPIs in March 2020.

Methods

i) Study design

Our study comprised: 1) a cross-sectional pathogen detection study covering September 2016 to July 2023 and 2) a cross-sectional study of antibody-mediated immunity to *S. pyogenes* and common respiratory viruses before and after introduction of NPIs in March 2020. Both investigations focused on children attending hospitals in Europe recruited to one of two EU-funded prospective, multicentre observational studies of febrile illness during childhood: PERFORM[17] recruiting from 19 hospitals in nine European countries between September 2016 and March 2020, and DIAMONDS recruiting from 20 hospitals in six European countries between March 2020 and July 2023.[18]

Across both studies children aged 0-18 years presenting with fever or suspected infection who were sufficiently unwell to require blood tests were recruited from emergency departments, paediatric inpatient wards and paediatric intensive care units. Additionally non-febrile children who were undergoing blood sampling for unrelated reasons were recruited as controls, providing they had not experienced fever or received a vaccination in the previous three weeks.[17] As previously described, each child recruited to the study was

assigned a final diagnostic category on the basis of the available clinical, laboratory and imaging data by at least two experienced paediatricians using an algorithm modified from previous iterations[19] to enhance detection of inflammatory disease (Supplementary Figure 1).

For our pathogen detection study, all children recruited aged 0-4 years to PERFORM and DIAMONDS (including controls) were eligible if a throat swab had been taken during recruitment as part of our centralised molecular testing programme, which was performed retrospectively as previously described to generate a comprehensive view of the pathogens present in the study population.[17] Additionally, as a sensitivity analysis, we repeated our analysis in all children recruited to the studies aged 0-18 years.

For our antibody-mediated immunity study, we focused on a subset of children aged 0-4 years recruited to PERFORM and DIAMONDS that were not in the diagnostic categories representing definite or potentially life-threatening bacterial or viral infections, or definite inflammatory diagnoses (Supplementary Figure 1). Further details are described in the Supplementary Methods.

ii) Data sources

De-identified clinical and demographic data were obtained from the PERFORM and DIAMONDS research databases derived from standardised case report forms. Children in definite bacterial, definite viral or unknown bacterial or viral diagnostic categories, and 10% of all other categories, were cross-checked for inconsistencies, as previously described.[17]

For our pathogen detection study, dry flocked throat swabs stored in eNAT™ media were tested retrospectively as part of our centralised molecular testing programme on the MAGPIX® system by Luminex Diasorin, using the NxTAG™ Respiratory Pathogen Panel (RPP).[17] This gave results for 16 viral and three bacterial targets from which, for this

analysis, we focused on influenza A (subtypes H1 and H3), influenza B, respiratory syncytial virus (RSV) (subtypes A and B), and common cold coronaviruses (HKU1, NL63, 229E and OC43). Additionally, we used quantitative PCR (qPCR) to detect *S. pyogenes* targeting the gene for DNase B using a previously described method developed at Micropathology Ltd.[17] Finally, for samples collected from 2020 onwards, we used a reverse transcription qPCR, also developed at Micropathology Ltd, to detect SARS-CoV-2 targeting the N gene as previously described.[20]

To measure antibody-mediated immunity to *S. pyogenes*, we adapted a previously reported enzyme-linked immunosorbent assay (ELISA) to measure absorbance to *S. pyogenes* cell wall extracts[21,22] of two representative strain types associated with scarlet fever: H305 (*emm1*/M1)[23] and H690 (*emm12*/M12).[24] Further details of the assays are described in the Supplementary Methods. Briefly, following optimisation, cell wall was extracted from overnight cultures of H305 and H690, dialysed overnight and concentrated using a centrifugal filter unit. Extracted cell wall was coated on to 96-well plates, washed, blocked and incubated with serum diluted 1:1000 in blocking buffer in duplicate. Detection was using a Horseradish peroxidase-conjugated goat anti-human IgG Fc secondary antibody (Sigma-Aldrich®; Cat. A0170) with 3,3′,5,5′-Tetramethylbenzidine (Sigma-Aldrich®; Cat. T0565). Absorbance readings are reported relative to IVIG (Privigen, CSL Behring).

To measure antibody-mediated immunity to common respiratory viruses, sera from a subset of children diluted 1:5000 was further tested for total IgG reactivity to viral analytes using the MSD V-PLEX Respiratory Panel 1 and the V-PLEX COVID-19 Coronavirus Panel 3 kits according to the manufacturer's protocol. Each sample was tested for reactivity to 15 analytes from which, for this analysis, we focused on: hemagglutinin from two influenza A viruses (A/Michigan/45/2015[H1N1] and A/Hong Kong/4801/2014[H3N2]) and two influenza B viruses (B/Phuket/3073/2013 and B/Brisbane/60/2008); prefusion F-protein from RSV;

spike proteins from four common cold coronaviruses (HKU1, NL63, 229E and OC43); and nucleocapsid, spike and spike receptor binding domain (RBD) from SARS-CoV-2.

Finally, to add context to our findings, we reviewed statutory notifications of iGAS and scarlet fever to the UK Health Security Agency (UKHSA) from across England made between January 2016 and December 2022. Further details are described in the Supplementary Methods.

iii) Statistical analysis

Data were inspected for missing and outlying points; categorical variables were tabulated, and continuous variables were summarised in histograms. All analyses were performed using R version 4.3.2[25] and plots were generated using the *ggplot2* package.[26] Our sample size was determined by the number of samples available at the time that we conducted the experiments and capacity to run samples on the MSD platform rather than a formal sample size calculation.

For the pathogen detection study, data were transformed to a times series using the R package *tsibble*.[27] Monthly totals and the proportion of positive samples were calculated with both the two influenza A subtypes and the four common cold coronaviruses each pooled together.

For the antibody-mediated immunity study, we divided children into two periods: those recruited before the pandemic, defined as having a serum sample dated before 23rd March 2020, the start of the first government mandated lockdown in the UK ("non-pharmaceutical intervention", NPI); and those recruited during or after the pandemic, defined as having a serum sample dated after 22nd April 2020. For simplicity, time before 23rd March 2020 is termed 'before NPI' while time after 22nd April 2020 is termed 'after NPI' with a month gap to reflect at least one half-life of natural IgGs.[28]

To assess the relationship between age and reactivity before and after introduction of NPIs, we plotted absorption to *S. pyogenes* relative to IVIG and reactivity to the viral antigens against age as a continuous variable. For subsequent analyses, we divided age at time of sampling into six bands beginning at: 0 months, 6 months, 1 year, 2 years, 3 years and 4 years. The first year was divided in half to allow appreciation of the decay of maternally derived antibody. We tested for differences relative to pandemic within each age band using a Wilcoxon rank-sum test, or the Kruskal-Wallis in sensitivity analyses with additional time periods.

To understand changes in the incidence of iGAS and scarlet fever among children aged 3-4 years, relative to those aged 0-2 years, we calculated yearly incidence rates for each disease for each age band based on the total number of notifications divided by the UK Office for National Statistics population estimate for England for that each bracket. We then examined the change in incidence of each disease in age band relative to the respective pre-pandemic average for 2016 to 2019, assessing statistical significance using Poisson regression and investigated interactions between age band and year using likelihood-ratio tests. We did not make adjustment for multiple testing because our primary analysis focused on changes in acquisition of immunity to S. pyogenes, and we did not consider it equally likely that all age-groups or individual viruses would be influenced by timing related to the pandemic.

v) Research ethics and governance

Ethical approval was obtained at Imperial College London as coordinating site for both PERFORM (Reference: 16/LO/1684) and DIAMONDS (Reference: 20/HRA/1714) as well as each participating centre (Supplementary Tables 1 and 2). All children were recruited with informed parental consent, and assent from older children.

Results

Between September 2016 and July 2023, a total of 5,484 children aged 0-4 years were recruited to the PERFORM and DIAMONDS studies at sites within Europe. Of these, 1,942 (35.4%) had valid throat swab PCR results available, including 1,449 pre-pandemic samples, and 493 after NPI introduction (Table 1). After exclusions, antibody titres to *S. pyogenes emm1* and *emm12* were available from 452 children aged 0-4 years (153, 33.7%, also with a valid throat swab PCR), while viral panel titres were available for 322 children (103, 32.0%, with a throat swab PCR) (Supplementary Figure 2).

In both the pathogen detection and antibody-mediated immunity subsets, characteristics of the participants were broadly similar before and after introduction of NPIs, although a higher proportion of samples afterwards had non-White European ethnicity and were recruited in the UK. Additionally, unlike before NPIs, assessment of reactivity to *S. pyogenes* after NPIs included 87 children (43.5%) from the unknown bacterial or viral infection category, 19 (9.5%) from uncertain infection or inflammation category, and one in the other cause of illness category.

In the pathogen detection study, a marked decrease in the prevalence of detected pathogens including RSV, common cold coronaviruses, and influenza viruses, was observed from March 2020 to July 2021, corresponding to the periods of social distancing and school closures (Figure 1). For example, RSV subtypes A and B were only detected in 3 of 16 months during the restrictions period while human coronaviruses other than SARS-CoV-2 were only detected in 2 of 16 months. Detection of *S. pyogenes* also declined during that period with the pathogen detected in samples in 5 of 16 months during the restrictions period compared to 36 of 43 of months previously. Similar changes were seen in our wider cohort of children aged 0-18 years (Supplementary Figure 3).

Among 252 children sampled from before the pandemic for the antibody-mediated immunity study, reactivity to *S. pyogenes* cell wall extract from *emm1* and *emm12* – which were highly correlated (*r*=0.94) – declined during the first year of life before rising over the remaining years studied. However, this pattern was altered among the 200 children sampled after introduction of NPIs (Figure 2A and 2B). Excluding 11 children (2.4%) in whom *S. pyogenes* was detectable by PCR at the time of sampling (potentially reflecting acute infection), the median absorbance relative to IVIG among children aged 3-4 years was significantly higher before compared with after (*S. pyogenes*: *emm1* before, n=87, median 0.35 IVIG relative units [RU], interquartile range [IQR], 0.10-0.65 vs *emm1* after, n=67, median, 0.13 RU, IQR 0.04-0.44, p=0.007; *emm12* before, n=87, median 0.51 RU, IQR, 0.18-0.76 vs *emm12* after, n=67, median, 0.21 RU, IQR 0.06-0.59, p=0.005, Figure 3). In multivariate linear regression models, normalised absorbance to both *emm1* and *emm12* was similar among 3-year-old children recruited after NPIs to that of 2-year-old children either before or afterwards (Figure 3A/3B). Similarly, children over 4-years old recruited after the pandemic had similar normalised absorbance to 3-year-old children recruited before pandemic. Further details including sensitivity analyses are described in Supplementary Results.

A similar age-related acquisition of immunity was seen in a subset of 230 children recruited prior to the pandemic and 92 recruited thereafter in whom antibody reactivity to key antigens from common respiratory viruses were assessed using the MSD assay. Among children aged 3-4 years, excluding eight with detectable RSV at the time of sampling, reactivity to RSV was significantly lower among children recruited after introduction of NPIs (Figure 3C; before, n=76, median 141782 mesoscale units [MU], IQR, 78103-423103, after, n=30, median 49604 MU, IQR, 31065-120655, p<0.001). The statistical relationship between RSV reactivity and age was broadly similar to that observed for *S. pyogenes* although, allowing for the smaller sample size, the effect of NPIs was only statistically significant in the children aged 3 years (Supplementary Table 5).

Correlation between reactivity to individual antigens was mostly explained by age but otherwise weak unless originating from the same or closely related viruses (Supplementary Figure 5). Although some other age-related changes were apparent, there were no consistent pandemic-related patterns of reactivity to individual influenza (Supplementary Figure 6) or common cold coronavirus antigens (Supplementary Figure 7). However, unlike the influenza viruses, reactivity to common cold coronaviruses in aggregate was also lower in children aged 3-4 years recruited after NPIs (Figure 4). In contrast to the other viruses, reactivity to SARS-CoV-2 antigens increased after NPIs, a pattern that was most apparent in samples obtained from July 2021 onwards (Supplementary Figure 8). However, this increase was not apparent in all age groups (Supplementary Figure 9).

Finally, in comparison to the pre-pandemic average, UKHSA notification data for England indicated a significantly greater increase in the incidence rate of iGAS infection but not scarlet fever during 2022 among children aged 3-4 years compared to those aged 0-2 years (Supplementary Figure 10).

Discussion

We found a significant reduction in antibody concentrations against *S. pyogenes* and RSV in children at 3-4 years of age attending hospitals in the UK and Europe in the first three years after introduction of NPIs to combat the COVID-19 pandemic in March 2020. Although we cannot infer causality from these data, this apparent reduction in antibody-mediated immunity coincides with the exact age group who experienced the greatest increase in life-threatening *S. pyogenes* incidence after NPIs were removed. Although Europe-wide data on *S. pyogenes* incidence were not available, our review of UKHSA data for England confirmed this age group experienced the greatest increase. Moreover, the increase in iGAS cases occurred substantially earlier in the season than is typical, coinciding with a more seasonal but nonetheless equally substantial increase in respiratory viruses, to which our data suggest children were also more susceptible. Ultimately these findings serve as a reminder

of the vulnerability of children to *S. pyogenes* infection and the urgent need to develop a vaccine to prevent this disease.

The differences observed in our study appear restricted to pre-school-aged children who are in the process of acquiring adaptive immunity to *S. pyogenes.* Nonetheless, our multivariate analyses suggest that on average the antibody-mediated immunity of children recruited after introduction of NPIs is a year behind that of those recruited before the pandemic. Thus, given the vital importance of antibody in preventing *S. pyogenes* infection, scaled to the population this delayed acquisition of immunity is likely to have contributed to the increase of iGAS infections observed during 2022 to 2023. While the dataset pertaining to viral antigens was smaller, acquisition of immunity to RSV also appeared delayed although the effect appeared limited to 3-4 year-old children. To some extent this difference may reflect an artifact of measuring reactivity to a single RSV antigen rather than the composite of the entire *S. pyogenes* cell wall, but further work would be required to investigate whether reactivity to single *S. pyogenes* antigens is acquired at a faster rate relative to the composite. Our data also suggest NPIs may have altered acquisition of immunity to common cold coronaviruses but not influenza viruses, at least as assessed in this multiplex assay. This result may reflect the complex range of factors that influence population-level immunity to influenza viruses including use of influenza vaccinations.

Similar findings relating to *S. pyogenes* and RSV antibody levels have been reported by one study focusing on adult blood donors sampled in New Zealand.[29] While limited to adults, who experienced a more marginal increase in iGAS during 2022 to 2023[30,31] that study benefited from repeated measures from the same individuals and assessed individual *S. pyogenes* antigens rather than our composite cell wall extract approach. Thus the concordance with our results in children is notable and supportive of our conclusions. Other authors have reported waning antibody-mediated immunity to RSV in women of child-bearing age and infants in Canada[32] and across the age-spectrum in the Netherlands.[33] Another group

working in China observed similar age-specific changes in RSV antibodies among children aged 0-4 years, finding a pronounced decline in children aged 3-4 years during the pandemic.[34]

Strengths of our study include a carefully characterised cohort including well defined diagnostic categories and exclusion of concurrent respiratory infections. Keeping in mind the limited extent to which it is possible to sample healthy children, most are representative of those aged 0-4 years in the general population. Although a wider range of diagnostic categories were included among children recruited during and after the pandemic, adjustment for these differences in our multivariate analyses did not alter our results. Additionally, our study is limited by relatively small sample size and to children aged 0-4 years. Accordingly, our estimates of the differences in antibody levels before and after the pandemic may be imprecise, and further work would be needed to investigate whether the reduction in *S. pyogenes* binding persisted further into childhood. Moreover, we would have ideally extended the analysis of reactivity to viral antigens to a larger number of samples but that was beyond the scope of the current project. In future work we will investigate the extent to which the patterns observed for *S. pyogenes* cell wall antigen would be recapitulated in binding to single antigens. Finally, our work was limited to measurement of total IgG to a limited range of antigens, and we have not yet studied other isoforms or subclasses of antibody, or more unbiased approaches to characterising antibody or other aspects of adaptive immunity to *S. pyogenes*.

In summary, our findings provide an immunological explanation for the upsurge in severe *S. pyogenes* infections affecting younger children and the wider population in 2022-2023. Most importantly, these findings strengthen the case for *S. pyogenes* vaccine development to protect vulnerable groups in the wider population.[35]

Acknowledgements

We are grateful to all patients and families that contributed towards this study, as well as all members of the DIAMONDS and PERFORM consortia, who are listed in the supplementary appendix.

Funding:

This project received funding under the European Union's Horizon 2020 Research and Innovation program under grant agreement number 668303 and 848196. Additional support was received from the Wellcome Trust [222098/Z/20/Z (TP) and 215539/Z/19/Z (KH and SS)], UK Research and Innovation (UKRI) [EP/S023283/1 (SCW)] and the Medical Research Council [MR/W00710X/1 (AL)]. Further support was received from the National Institute for Health and Care Research (NIHR) Biomedical Research Centres at Imperial College London and the University of Newcastle, the UK NIHR Academic Clinical Lectureship program (MJC), and Imperial College London Clinical Academic Training Office (KD). These funders had no role in study design, data collection, analysis, interpretation of data, preparation of the manuscript or decision to publish.

Footnote

This research was funded in part by the Wellcome Trust [222098/Z/20/Z and 215539/Z/19/Z]. For the purpose of open access, the author has applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

Contribution statement

T Parks had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: T Parks, S Sriskandan, M Levin, A Cunnington

Acquisition and interpretation of data: All authors

Analysis of the data, including statistical analysis: T Parks, S Channon-Wells, K Dokal, D Estrada-Rivadeneyra

Drafting of the manuscript: T Parks, S Channon-Wells, K Dokal, S Sriskandan, M Levin

Critical review of the manuscript for important intellectual content: All authors contributed to critically reviewing the manuscript and approved the final version. Everyone is agreeable to being accountable for all aspects of the work.

Conflict of Interest Disclosures:

P Agyeman reported receiving grants to institution from the MedTrix Group, Switzerland, during the conduct of the study. P Agyeman reported being a scientific advisory board member for Sanofi during the conduct of the study. R Basmaci reported receiving personal fees from Sanofi and MSD during the conduct of the study. ED Carrol report being a scientific advisory board member for Thermofisher, bioMerieux, and Danaher, with grants to institution, during the conduct of the study. MJ Carter reported receiving grants for laboratory materials from the Rosetrees Trust and BactiVac during the conduct of the study. F Martinon-Torres reported receiving grants to institution from Sanofi-Astra Zeneca, GSK, and Pfizer during the conduct of the study, and reported consulting/advisory relationships with GSK Vaccines SRL, Pfizer Inc, Sanofi Pasteru, Janssen Pharmaceuticals, MSD, Seqirus Pty Ltd, Biofabri, and Astra Zeneca, during the conduct of the study. F Martinon-Torres reported receiving personal fees from Pfizer, MSD, GSK, and Sanofi during the conduct of the study, and reported being a member (unpaid) of The European Technical Advisory Group of Experts on Immunization (ETAGE - WHO), and coordinator of Spanish Pediatric Critical Trials Network and the WHO collaborating centre for vaccine Safety of Santiago de Compostela, during the conduct of the study. F Martinon-Torres reported being a principal investigator in randomised controlled trials of Ablynx, Abbot, Seqirus, Sanofi Pasteur MSD, Sanofi Pasteur, Cubist, Wyeth, Merck, Pfizer, Roche, Regeneron, Jansen, Medimmune, Novavax, Novartis and GSK during the conduct of the study. M Mommert-Tripon reported being an employee of bioMerieux during the conduct of the study. DR Owens reporting being

an investigator on studies funded or sponsored by vaccine manufacturers including AstraZeneca, GlaxoSmithKline, Janssen, Medimmune, Merck, Pfizer, Sanofi, Iliad, Moderna and Valneva during the conduct of the study, with payments to institution. MJ Peters reported receiving grants to institution from the Engineering and Physical Sciences Research Council (UK), UK National Institute of Health and Social Care Senior Investigator Award, and UK National Institute of Health and Social Care Health Technology Assessment programme (UK) during the conduct of the study. MJ Peters reported receiving personal fees from the Ministry of Justice (UK) during the conduct of the study. M Pokorn reported receiving grants to institution from Pfizer and personal fees from Pfizer and MSD during the conduct of the study. A Pollard reported receiving grants to institution from the Gates Foundation, Wellcome Trust, Cepi, MRC, NIHR, AstraZeneca, European Commission, and Serum Institute of India during the conduct of the study, and reported being the Chair of the Department of Health and Social Care's Joint Committee on Vaccination and Immunisation, a member of the WHOs SAGE, and chair of WHOs Salmonella TAG during the conduct of the study. A Pollard reported being a contributor to intellectual property licensed by Oxford University Innovation to AstraZeneca during the conduct of the study. A Pollard reported receiving personal fees from Shionogi and Moderna during the conduct of the study. I Rivero-Calle reported receiving grants to institution as investigator in clinical vaccine trials from Ablynx, Abbot, Seqirus, Sanofi Pasteur MSD, Sanofi Pasteur, Cubist, Wyeth, Merck, Pfizer, Roche, Regeneron, Jansen, Medimmune, Novavax, Novartis, and GSK during the conduct of the study, and reported being a member of the Board of Directors of the Vaccine Advisory Committee of the Spanish Association of Pediatrics (AEP), a member of the Board of Directors of the Spanish Society for Pediatric Infectious Diseases (SEIP), and a member of the Executive Committee of the Pediatric Research Platform of the Spanish Association of Pediatrics (INVEST-AEP) during the conduct of the study. I Rivero-Calle reported receiving personal fees from Pfizer, MSD, Sanofi, and GSK during the conduct of the study. L Schlapbach reported receiving grants from the NOMIS Foundation, Thomas & Doris Ammann Foundation, NIH, SPHN, PHRT, MRFF, NHMRC and the Horizon-2020 program

during the conduct of the study. CF Shen reported receiving grants to institution from the National Science and Technology Council, Taiwan during the conduct of the study. A Sulik reported receiving grants to institution from the Medical University of Bialystok during the conduct of the study. M Tsolia reported receiving grants to institution as investigator in clinical vaccine trials and other studies from MSD during the conduct of the study, and reported being a scientific advisory board member for Pfizer (unpaid), MSD (unpaid), and Sanofi during the conduct of the study. M Tsolia reported being president and a board member of the Hellenic Society for Pediatric Infectious Diseases during the conduct of the study, and reported receiving personal fees from MSD and Sanofi during the conduct of the study. U von Both reported being the chair of the European Society for Paediatric Infectious Diseases (ESPID) committee for research, a member of the ESPID extended board, and member of the DGPI extended board during the conduct of the study, and reported receiving personal travel support from ESPID during the conduct of the study. C Fink reported receiving payments to institution of standardised diagnostic charges for laboratory work as part of the conduct of the study, and reported being chairman of the Medical and Life Sciences Research Fund UK Charity during the conduct of the study. M Kaforou reported receiving grants to institution from the Rosetrees Trust during the conduct of the study. T Parks reported receiving grants to institution from the Leducq Foundation, British Medical Association, British Infection Association, and Medical Research Council during the conduct of the study. No other disclosures were reported.

Data Sharing Statement:

A subset of the data that support the findings of this study will be made available upon acceptance for publication in a peer-reviewed journal. This will include deidentified reactivity data for M1, M12 and RSV assays as used in our main statistical analysis. Complete raw data will not be publicly available due to privacy concerns and ethics restrictions.

Table 1. Baseline characteristics of participants

Variable	**Pathogen detection**		**Antibody mediated immunity**			
Assay	Multiplex PCR		ELISA to *S. pyogenes*		MSD multiplex	
Stage	Pre (n=1449)	Post (n=493)	Pre (n=252)	Post (n=200)	Pre (n=230)	Post (n=92)
Male sex, n (%)	798 (55.1)	269 (54.7)	147 (58.3)	127 (63.5)	136 (59.1)	60 (65.2)
Age (months),						
Median (IQR)	19.7 (8.2-38.1)	20.7 (9.1-38.1)	26.8 (11.6-45.3)	25.3 (12.2-42.8)	26.3 (11.3-43.0)	25.7 (15.3-42.2)
Ethnicity, n (%)						
Afro-Caribbean	6 (0.4)	0	<5	<5	<5	<5
Asian	89 (6.4)	86 (18.7)	10 (4.1)	17 (8.9)	10 (4.5)	6 (6.7)
Black African	34 (2.4)	45 (9.8%)	6 (2.4)	19 (9.9)	5 (2.2)	5 (5.6)
Middle-Eastern	20 (1.4)	8 (1.7)	<5	<5	<5	0
White European	1155 (82.6)	272 (59.3)	218 (89.0)	128 (67.0)	197 (88.3)	65 (73.0)
Mixed	37 (2.6)	17 (3.7)	<5	8 (4.2)	<5	5 (5.6)
Other	57 (4.1)	31 (6.8)	<5	16 (8.5)	<5	6 (6.7)
Country						
U.K.	411 (28.4)	421 (85.4)	112 (44.4)	134 (67.0)	105 (45.6)	48 (52.2)
E.U.	1038 (71.6)	72 (14.6)	140 (55.5)	66 (33.0)	125 (54.3)	44 (47.8)

Diagnostic category						
Definite bacterial	183 (12.6)	55 (11.2)	0	0	0	0
Probable bacterial	217 (15.0)	39 (7.9)	0	0	0	0
Bacterial syndrome	140 (9.7)	23 (4.7)	0	0	0	0
Unknown bacterial or viral	217 (15.0)	50 (10.1)	0	87 (43.5)	0	0
Viral syndrome	122 (8.4)	65 (13.2)	0	0	0	0
Probable viral	215 (14.8)	46 (9.3)	98 (38.9)	52 (26.0)	94 (40.9)	52 (56.5)
Definite viral	165 (11.4)	108 (22.0)	0	0	0	0
Inflammatory syndrome	24 (1.7)	55 (11.1)	0	0	0	0
Other phenotype*	71 (4.9)	47 (9.5)	0	20 (10.0)	0	0
Control or trivial illness	95 (6.6)	5 (1.0)	154 (61.1)	41 (20.5)	136 (59.1)	40 (43.5)

*Comprising uncertain infection or inflammation, parasitic infections and other unknown cause of illness.



Figure 1. Detection of *S. pyogenes* and viral pathogens by PCR among children aged 0-4 years recruited to the PERFORM and DIAMONDS studies during September 2016 to August 2023. The monthly number of valid samples processed is shown in the first plot followed by the monthly number of positives for each pathogen indicated using grey bars. The red line indicates the monthly percentage of positive samples, plotted on the same scale. Dashed vertical lines indicate the dates of introduction and lifting of restrictions in the UK, as described in the Supplementary Methods. RSV, respiratory syncytial virus; HCoV, common cold coronaviruses 229E, OC43, NL63 and HKU1 (combined); SARSCoV2, Severe acute respiratory syndrome coronavirus 2.



Figure 2. Reactivity to *S. pyogenes* and RSV antigens by age. Scatter plots show reactivity before NPsI (black) and after NPIs (red) March 2020 with a trend line and 95% confidence interval estimated by LOESS regression: **A**. Absorption to M1 relative to IVIG, **B.** Absorption to M12 relative to IVIG, **C.** Reactivity to RSV F-protein.



Figure 3. Reactivity to *S. pyogenes* and RSV antigens by age band. Box plots show reactivity before NPIs (black) and after NPIs (red) March 2020 with the difference between groups assessed by a Wilcoxon rank-sum test. **A**. Absorption to *emm1* relative to IVIG, **B.** Absorption to *emm12* relative to IVIG, **C.** Reactivity to RSV F-protein.



Figure 4. Aggregate reactivity to **A**. circulating influenza A and influenza B viruses and **B**. common cold coronaviruses

References

1. Guy R, Henderson KL, Coelho J, et al. Increase in invasive group A streptococcal infection notifications, England, 2022. *Euro Surveill*. 2023;28(1). doi:10.2807/1560-7917.ES.2023.28.1.2200942
2. UK Health Security Agency. Group A streptococcal infections: first update on seasonal activity in England, 2022 to 2023. Published 2023. Available at: https://www.gov.uk/government/publications/group-a-streptococcal-infections-activity-during-the-2022-to-2023-season/group-a-streptococcal-infections-first-update-on-seasonal-activity-in-england-2022-to-2023. Accessed April 9, 2025.
3. van Kempen EB, Bruijning-Verhagen PCJ, Borensztajn D, et al. Increase in Invasive Group a Streptococcal Infections in Children in the Netherlands, A Survey Among 7 Hospitals in 2022. *Pediatr Infect Dis J*. 2023;42(4):e122-e124. doi:10.1097/INF.0000000000003810
4. Lees EA, Williams TC, Marlow R, et al. Epidemiology and Management of Pediatric Group A Streptococcal Pneumonia With Parapneumonic Effusion: An Observational Study. *Pediatr Infect Dis J*. 2024;43(9):841-850. doi:10.1097/INF.0000000000004418
5. Johannesen TB, Munkstrup C, Edslev SM, et al. Increase in invasive group A streptococcal infections and emergence of novel, rapidly expanding sub-lineage of the virulent Streptococcus pyogenes M1 clone, Denmark, 2023. *Euro Surveill*. 2023;28(26). doi:10.2807/1560-7917.ES.2023.28.26.2300291
6. van der Putten BCL, Vlaminckx BJM, de Gier B, Freudenburg-de Graaf W, van Sorge NM. Group A Streptococcal Meningitis With the M1UK Variant in the Netherlands. *JAMA.* 2023;329(20):1791-1792. doi:10.1001/jama.2023.5927
7. Vieira A, Wan Y, Ryan Y, et al. Rapid expansion and international spread of M1(UK) in the post-pandemic UK upsurge of Streptococcus pyogenes. *Nat Commun*. 2024;15(1):3916. doi:10.1038/s41467-024-47929-7
8. Wrenn K, Blomquist PB, Inzoungou-Massanga C, et al. Surge of lower respiratory tract group A streptococcal infections in England in winter 2022: epidemiology and clinical profile. *Lancet*. 2023;402(suppl 1). doi:10.1016/S0140-6736(23)02095-0
9. Public Health Wales, UK Health Security Agency, National Child Mortality Database England, Public Health Scotland, National Hub for Reviewing and Learning from the Deaths of Children and Young People, and Public Health Agency Northern Ireland. 4 Nations rapid review of iGAS deaths in children (2024). Published 2024. Available at: https://phw.nhs.wales/services-and-teams/child-death-review/child-death-review-publications/. Accessed April 9, 2025.
10. Taylor A, Whittaker E. The Changing Epidemiology of Respiratory Viruses in Children During the COVID-19 Pandemic: A Canary in a COVID Time. *Pediatr Infect Dis J*. 2022;41(2):e46-e48. doi:10.1097/INF.0000000000003396
11. UK Health Security Agency. Scarlet fever: symptoms, diagnosis and treatment (2014). Published 2014. Available at: https://www.gov.uk/government/publications/scarlet-fever-symptoms-diagnosis-treatment. Accessed April 9, 2025.
12. Lamagni T, Guy R, Chand M, et al. Resurgence of scarlet fever in England, 2014-16: a population-based surveillance study. *Lancet Infect Dis*. 2018;18(2):180-187. doi:10.1016/S1473-3099(17)30693-X
13. Cohen R, Ashman M, Taha MK, et al. Pediatric Infectious Disease Group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap? *Infect Dis Now*. 2021;51(5):418-423. doi:10.1016/j.idnow.2021.05.004
14. Ball P. Immunity debt: does it really exist? The Guardian. Available at: https://www.theguardian.com/science/2023/jan/14/immunity-debt-does-it-really-exist. Accessed February 17, 2025
15. Sheikh K. The Case of the Never-Ending Illness. *The New York Times*. December 15 2023. Available at: https://www.nytimes.com/2023/12/15/well/covid-winter-sick-cold.html. Accessed April 9, 2025

16. Nygaard U, Holm M, Rabie H, Rytter M. The pattern of childhood infections during and after the COVID-19 pandemic. *Lancet Child Adolesc Health*. 2024;8(12):910-920. doi:10.1016/S2352-4642(24)00236-0
17. Shah P, Voice M, Calvo-Bado L, et al. Relationship between molecular pathogen detection and clinical disease in febrile children across Europe: a multicentre, prospective observational study. *Lancet Reg Health Eur*. 2023;32:100682. doi:10.1016/j.lanepe.2023.100682
18. DIAMONDS 2020. DIAMONDS: Making Diagnosis Personal. Published 2025. Available at: https://www.diamonds2020.eu/. Accessed April 9, 2025
19. Nijman RG, Oostenbrink R, Moll HA, et al. A Novel Framework for Phenotyping Children With Suspected or Confirmed Infection for Future Biomarker Studies. *Front Pediatr*. 2021;9:688272. doi:10.3389/fped.2021.688272
20. Calvez R, Taylor A, Calvo-Bado L, Fraser D, Fink CG. Molecular detection of SARS-CoV-2 using a reagent-free approach. *PLoS One*. 2020;15(12):e0243266. doi:10.1371/journal.pone.0243266
21. Turner CE, Dryden M, Holden MT, et al. Molecular analysis of an outbreak of lethal postpartum sepsis caused by Streptococcus pyogenes. *J Clin Microbiol*. 2013;51(7):2089-2095. doi:10.1128/JCM.00679-13
22. Reglinski M, Gierula M, Lynskey NN, Edwards RJ, Sriskandan S. Identification of the Streptococcus pyogenes surface antigens recognised by pooled human immunoglobulin. *Sci Rep*. 2015;5:15825. doi:10.1038/srep15825
23. Sriskandan S, Unnikrishnan M, Krausz T, Cohen J. Molecular analysis of the role of streptococcal pyrogenic Exotoxin A (SPEA) in invasive soft-tissue infection resulting from Streptococcus pyogenes. *Mol Microbiol*. 1999;33(4):778-790. doi:10.1046/j.1365-2958.1999.01525.x
24. Turner CE, Pyzio M, Song B, et al. Scarlet Fever Upsurge in England and Molecular-Genetic Analysis in North-West London, 2014. *Emerg Infect Dis*. 2016;22(6):1075-1078. doi:10.3201/eid2206.151726
25. R Core Team. R: A language and environment for statistical computing. Published 2023. Available at: https://www.R-project.org/. Accessed April 9, 2025.
26. Wickham H. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York; 2016.
27. Wang E, Cook D, Hyndman RJ. A New Tidy Data Structure to Support Exploration and Modeling of Temporal Data. *Journal of Computational and Graphical Statistics*. 2020;29(3):466-478. doi:10.1080/10618600.2019.1695624
28. Foss S, Sakya SA, Aguinagalde L, et al. Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria. *Nat Commun*. 2024;15(1):2007. doi:10.1038/s41467-024-46321-9
29. Lorenz N, James A, Van Rooyen T, et al. Decline of Antibodies to Major Viral and Bacterial Respiratory Pathogens During the COVID-19 Pandemic. *J Infect Dis*. 2025;231(1):e77-e81. doi:10.1093/infdis/jiae611
30. UK Health Security Agency. Group A streptococcal infections: 15th update on seasonal activity in England, 2022 to 2023. Published 2023. Available at: https://www.gov.uk/government/publications/group-a-streptococcal-infections-activity-during-the-2022-to-2023-season. Accessed April 9, 2025.
31. Ammar S, Duff P, Galloway Y, Lees J, Morgan H. Invasive group A streptococcal infection in New Zealand, 2023 (Ministry of Health). Published 2023. Available at: https://www.esr.cri.nz/digital-library/invasive-group-a-streptococcal-infection-in-new-zealand-2023/. Accessed April 9, 2025.
32. Reicherz F, Xu RY, Abu-Raya B, et al. Waning Immunity Against Respiratory Syncytial Virus During the Coronavirus Disease 2019 Pandemic. *J Infect Dis*. 2022;226(12):2064-2068. doi:10.1093/infdis/jiac192
33. den Hartog G, van Kasteren PB, Schepp RM, Teirlinck AC, van der Klis FRM, van Binnendijk RS. Decline of RSV-specific antibodies during the COVID-19 pandemic. *Lancet Infect Dis*. 2023;23(1):23-25. doi:10.1016/S1473-3099(22)00763-0

34. Jiang W, Xu L, Wang Y, Hao C. Exploring immunity debt: Dynamic alterations in RSV antibody levels in children under 5 years during the COVID-19 pandemic. *J Infect*. 2024;88(1):53-56. doi:10.1016/j.jinf.2023.10.019
35. Gregory CJ, Okaro JO, Reingold A, et al. Invasive group A streptococcal infections in 10 US states. *JAMA*. Published online April 7, 2025. doi:10.1001/ jama.2025.0910


Samples
S. pyogenes
Influenza A
Influenza B
RSV A
RSV B
HCoV
SARSCoV2
0
10
20
30
40
50
60
80
2017
2018
2019
2020
2021
2022
2023


A
1.00
0.10
0.01
emm11 absorption relative to IVIG (log10-scale)
0
1
2
3
4
5
Age (years)


B
1.00
0.10
0.01
emm12 absorption relative to IVIG (log10-scale)
0
1
2
3
4
Age (years)


A
p=0.631 p=0.164 p=0.313 p=0.508 p=0.037 p=0.026
emm1 absorption relative to IVIG (log10-scale)
1.00
0.10
0.01
0 months
6 months
1 year
2 years
3 years
4 years
B
p=0.619 p=0.070 p=0.665 p=0.443 p=0.013
emm12 absorption relative to IVIG (log10-scale)
1.00
0.10
0.01
0 months
6 months
1 year
2 years
3 years


A
p=0.130 p=0.220 p=0.490 p=0.900 p=0.590 p=0.600
Mean-rank across influenza assays
2
0
-2
0 months
6 months
1 year
2 years
3 years
4 years
B
p=0.735 p=0.395 p=0.110 p=0.650 p=0.021 p=0.
Mean-rank across HCoV assays
2
0
-2
0 months
6 months
1 year
2 years
3 years
4 years